pRNA: A Safe，Stable and Large Capacity Molecular Vehicle for Gene Therapy

China Biotechnology

2007, Vol. 27

Issue (6): 96-100 DOI:

pRNA: A Safe，Stable and Large Capacity Molecular Vehicle for Gene Therapy

Download:

HTML

PDF(522KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract

Abstract:　 The molecular delivery vectors used in gene therapy need provide the features of safety，stability, efficiency and capacity. The current studies on the structure and action mechanism of pRNA, a packaging RNA of phageΦ29, showed that pRNA with multiple binding sites can through cell membrane easily and escort exogenous molecules to target cell, without inducing immune reaction. As an ideal nano-scale gene therapy vehicle, pRNA presents a promising application in delivering multiple therapeutic components to detect and treat human diseases.

Key words： pRNA multiple molecular vehicle gene therapy safety

Received: 08 January 2007 Published: 25 June 2007

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

. pRNA: A Safe，Stable and Large Capacity Molecular Vehicle for Gene Therapy. China Biotechnology, 2007, 27(6): 96-100.

URL:

https://manu60.magtech.com.cn/biotech/ OR https://manu60.magtech.com.cn/biotech/Y2007/V27/I6/96

[1]	LIU Xu-xia,YANG An-ke. An Analysis of the U.S. SECURE Rule and Its Enlightenment to China[J]. China Biotechnology, 2021, 41(9): 126-135.

[2]	ZHAO Xiao-yu,XU Qi-ling,ZHAO Xiao-dong,AN Yun-fei. Enhancing Lentiviral Vector Transduction Efficiency for Facilitating Gene Therapy[J]. China Biotechnology, 2021, 41(8): 52-58.

[3]	MA Li-li,YI Pan-pan,AO Ni-hua,JIAO Hong-tao,LEI Rui-peng,LIU Huan. A Study of Interdisciplinarity in Biosafety Research Based on Discipline Categories and Enrichment Analysis[J]. China Biotechnology, 2021, 41(12): 116-124.

[4]	XU Ying-yong. Current Status and Challenges of Gene Therapy Products[J]. China Biotechnology, 2020, 40(12): 95-103.

[5]	CHEN Qing-yu,WANG Xian-zhong,ZHANG Jiao-jiao. Application of Gene Technology in the Treatment of Type 2 Diabetes Mellitus[J]. China Biotechnology, 2020, 40(11): 73-81.

[6]	Ya-li HAN,Guang-heng YANG,Yan-wen CHEN,Xiu-li GONG,Jing-zhi ZHANG. The Optimization of Self-deleting Lentiviral Vector Carrying Human β-globin Gene and Promoter[J]. China Biotechnology, 2018, 38(7): 50-57.

[7]	Jing WANG,Xin XU,Xue-yu WANG,Lun-guang YAO,Yun-chao KAN,Jun JI. Research Progress of Loop-Mediated Isothermal Amplification in Food Safety Testing[J]. China Biotechnology, 2018, 38(11): 84-91.

[8]	LIU Yi-xuan, BIAN Zhen, MA Hong-mei. Progress and Prospect of Cancer Gene Therapy[J]. China Biotechnology, 2016, 36(5): 106-111.

[9]	WANG Xu-jing, ZHANG Xin, LIU Pei-lei, WANG Zhi-xing. The Application and Safety Assessment of Stacked Transgenic Plant[J]. China Biotechnology, 2016, 36(4): 18-23.

[10]	MA Cai-yun, PANG Jin-hui, SHI Xiao-hua, HU Rui-fa. Malatesta's Transgenic Research: Citation Analysis and Relevant Evidence[J]. China Biotechnology, 2016, 36(4): 12-17.

[11]	XU Lin-jie, SUN Zhuo-jing, YANG Xiong-nian, ZHU Yong-hong, LIU Pei-lei. Cognition and Development of Genetic Modification from Perspective of Sciences[J]. China Biotechnology, 2016, 36(4): 30-34.

[12]	TAO Chang-li, HUANG Shu-lin. *Advances in Research on Optimization of Transgenic TCR* Pairing in TCR Gene Therapy**[J]. China Biotechnology, 2016, 36(3): 87-92.

[13]	LIU Rui-qi, WANG Wei-wei, WU Yong-yan, ZHAO Qiu-yun, WANG Yong-sheng, QING Su-zhu. Research Progress of CRISPR-Cas9 and Its Application in Gene Therapy[J]. China Biotechnology, 2016, 36(10): 72-78.

[14]	ZHU Shao-yi, GUAN Li-hong, LIN Jun-tang. CRISPR-Cas9 System and Its Applications in Disease Models[J]. China Biotechnology, 2016, 36(10): 79-85.

[15]	PANG Jin-hui, MA Cai-yun, FENG Yong-li, HU Rui-fa. Biosafety of Genetically Modified Crops: Scientific Evidence[J]. China Biotechnology, 2016, 36(1): 122-138.

Viewed

Full text

Abstract

Cited

Shared

Discussed